Muscle Wasting in ICU Patients: What Bioimpedance Analysis Reveals About COVID-19 Patients

A recent study titled "Assessment of muscle wasting in intensive care unit patients with and without COVID-19 using ultrasound imaging and bioimpedance analysis", published in the journal BMC Anesthesiology by authors Šostakaitė G, Šalčiūtė-Šimėnė E, Svetikienė M, Danilenko S, Klimašauskas A, and Šipylaitė J, sheds new light on muscle wasting in intensive care patients. Using a combination of ultrasound and bioimpedance analysis (BIA) – particularly the phase angle as a marker – it investigates how muscle loss develops in COVID-19 patients compared to non-COVID patients in the ICU. But what do the results really say? And what role does the psyche play in this context? I'll take a closer look at the study and show you what you can take away from it for your understanding of health and regeneration.

1. Cui Bono? The Trail of Money and Interests

First, the question: Who benefits from this study? The publication in BMC Anesthesiology suggests academic funding, and there are no explicit indications of industry support in the abstract. Nevertheless, the question remains whether the authors have connections to medical device manufacturers that sell ultrasound or BIA technologies. Such interests could influence the selection of methods or the interpretation. Without access to the full author declaration, this remains speculation, but it's a point you should keep in mind. The study primarily seems to aim at improving care in intensive care units – a legitimate goal that, however, does not protect against critical scrutiny.

2. The Methodological Ordeal: The Foundation of the Study

Let's take a close look at the methodology. The study is a prospective cohort study comparing muscle wasting in ICU patients with and without COVID-19. The sample comprises two groups, whose exact size is not specified in the abstract, which is already a first weakness. Measurements were taken using ultrasound (for direct visualization of muscle mass, particularly the M. quadriceps femoris) and bioimpedance analysis (BIA), with the phase angle used as an indicator of cell health and muscle quality. Data were collected over an unspecified period in the ICU. A control group outside the ICU is missing, which limits comparability.

A potential selection bias could exist: Are the COVID-19 patients composed differently from the non-COVID group due to the severity of their illness? Confounders such as age, pre-existing conditions, or medication intake (e.g., steroids, which promote muscle wasting) are not mentioned in the abstract. The validity of BIA also strongly depends on hydration status – a factor that is often compromised in ICU patients.